Systemic immunosuppressants

[1]

Overview & Definition

Systemic immunosuppressants are drugs given by the oral, intravenous, subcutaneous, or intramuscular route that dampen one or more limbs of the immune response in order to control inflammatory, autoimmune, and bullous skin disease. In dermatology they are the second line after optimised topical therapy and phototherapy, and they have transformed the prognosis of conditions such as pemphigus vulgaris, severe psoriasis, atopic dermatitis, and the autoimmune connective tissue diseases. Unlike topical agents, which act locally, these drugs reach every organ system — which is precisely why their benefit is matched by a burden of infection, cytopenia, organ toxicity, teratogenicity, and malignancy that the prescriber must manage for as long as the drug continues.[1][6]

The mental model that organises this entire topic is simple: for every agent, know the mechanism, dose, one mandatory pre-treatment test, the monitoring schedule, the headline toxicity, and the pregnancy category. The fellowship examiner will probe these six attributes for each drug, and a candidate who can recite them for the full class — not just methotrexate and azathioprine — will pass any viva on this material. [1]

[1]

Classification

The agents group naturally by mechanism into six families. This classification is worth memorising because it predicts the toxicity profile and the monitoring requirement of any member. [1]

Mechanisms of Action

Each family interrupts immunity at a distinct point in the inflammatory cascade. Understanding where a drug acts explains both its efficacy in a given disease and its particular toxicity. [1]

Corticosteroids diffuse into the cell, bind the cytosolic glucocorticoid receptor, and the complex translocates to the nucleus where it transrepresses pro-inflammatory transcription factors NF-kappa-B and AP-1. The net effect is reduced transcription of TNF, interleukin-1, interleukin-2, and interleukin-6, reduced prostaglandin and leukotriene synthesis via lipocortin induction, and apoptosis of lymphocytes. This breadth is the source of their power and of their side-effect profile, which touches glucose, bone, vasculature, eye, gut, muscle, and mood.[1]

Methotrexate is a folate analogue that competitively inhibits dihydrofolate reductase (DHFR) and thymidylate synthase, depleting tetrahydrofolate and halting DNA synthesis in rapidly dividing cells. At the low weekly doses used in dermatology, however, the dominant anti-inflammatory effect is mediated through accumulation of adenosine, which signals through the A2 receptor to suppress neutrophil adhesion and cytokine release. This duality — anti-proliferative at high (oncology) doses, anti-inflammatory at low (dermatology) doses — is the single most important pharmacological fact about the drug.[1][6]

Azathioprine is a pro-drug converted in the liver and red cells to 6-mercaptopurine, then by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to 6-thioguanine nucleotides that incorporate into DNA and arrest lymphocyte proliferation. Two enzymes terminate this pathway: thiopurine methyltransferase (TPMT) methylates 6-MP to inactive metabolites, and xanthine oxidase (XO) converts it to thiouric acid. Inherited deficiency of TPMT (~1 in 300 homozygous, ~10 percent heterozygous) shunts metabolism toward excessive 6-thioguanine accumulation and catastrophic myelosuppression — which is why TPMT is measured before the first dose.[3]

Ciclosporin is a cyclic peptide that binds cyclophilin inside the T cell; the complex inhibits calcineurin, preventing dephosphorylation of the nuclear factor of activated T cells (NFAT). Without dephosphorylation, NFAT cannot enter the nucleus, so interleukin-2 transcription falls and T-cell activation collapses. The same calcineurin pathway operates in the renal vasculature, which is why vasoconstrictive nephrotoxicity shadows efficacy.[1]

Mycophenolate mofetil is hydrolysed to mycophenolic acid, a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Because lymphocytes rely on de novo purine synthesis (they lack the salvage pathway that other cells use), IMPDH blockade selectively cripples B and T lymphocyte proliferation.[9]

Cyclophosphamide is a nitrogen mustard pro-drug hepatically activated to phosphoramide mustard, which cross-links DNA strands, and to acrolein, which is excreted in urine and toxic to bladder urothelium (the cause of haemorrhagic cystitis).[4]

Dapsone is a sulfone whose anti-inflammatory (not antibacterial, at dermatology doses) action comes from inhibition of myeloperoxidase and interference with integrin-mediated neutrophil adhesion, suppressing neutrophil-mediated cytotoxicity at the dermo-epidermal junction. [1]

Thalidomide and its analogues lenalidomide and pomalidomide bind cereblon, altering ubiquitination of transcription factors and down-regulating TNF-alpha; they also inhibit angiogenesis, relevant to their teratogenicity. [1]

The biologics are monoclonal antibodies (or receptor-Fc fusion proteins) that bind and neutralise a single extracellular cytokine or its receptor. The JAK inhibitors are oral small molecules that block phosphorylation inside the cell: cytokine receptors signal through JAK-STAT, and by occupying the kinase active site these drugs prevent STAT phosphorylation and downstream gene transcription for a broad set of interleukins.[7][10]

Indications & Patient Selection

The choice of agent is governed by the disease, its severity and tempo, the patient's comorbidities, reproductive plans, and the expected duration of treatment. A few pairings are near-mandatory and should be recalled as fixed associations. [1]

Methotrexate is first-line systemic for moderate-to-severe plaque psoriasis and psoriatic arthritis, and is widely used for atopic dermatitis, bullous pemphigoid, cutaneous T-cell lymphoma, and sarcoidosis.[1][6] Azathioprine is a workhorse for atopic dermatitis, pemphigus vulgaris (as a steroid sparer), bullous pemphigoid, chronic actinic dermatitis, and cutaneous lupus.[3] Ciclosporin is reserved for rapid control of severe, flaring psoriasis or atopic dermatitis and for pyoderma gangrenosum, always as a short bridge.[1] Mycophenolate mofetil suits pemphigus, bullous pemphigoid, and cutaneous lupus where azathioprine is poorly tolerated.[9] Cyclophosphamide is for the severe vasculitides (ANCA-associated, cryoglobulinaemic) and refractory pemphigus.[4] Dapsone is the drug of choice for dermatitis herpetiformis and linear IgA bullous dermatosis, and useful for the neutrophilic dermatoses.[3] Hydroxycarbamide is a third-line option for refractory psoriasis. Thalidomide treats erythema nodosum leprosum, refractory aphthae in Behcet disease, and cutaneous lupus.

For psoriasis, biologic therapies targeting TNF, IL-17 and IL-23 are established treatment options for moderate-to-severe disease, and dupilumab has demonstrated efficacy in randomised trials in children as young as 6 months with atopic dermatitis.[1][21] Several disease-first-line pairings are worth memorising because they appear repeatedly in vivas. For psoriasis, the ladder is methotrexate or acitretin as first conventional agent, ciclosporin for rapid crisis control, then an IL-23 or IL-17 inhibitor for moderate-to-severe or refractory disease. For atopic dermatitis, dupilumab is the first systemic biologic from infancy, with the JAK inhibitors (upadacitinib, abrocitinib, baricitinib) as oral alternatives and methotrexate, azathioprine, and ciclosporin as conventional options. For pemphigus vulgaris, rituximab plus a tapering prednisolone course is the modern standard, with mycophenolate or azathioprine as steroid sparers. For cutaneous lupus, hydroxychloroquine is first-line (5 mg/kg/day), with methotrexate, mycophenolate, or belimumab for refractory disease. For dermatitis herpetiformis, dapsone is pathognomonic, combined with a strict gluten-free diet for the underlying coeliac-type enteropathy.

Choosing Between Agents

When two agents could treat the same disease, the differentiating questions are toxicity, onset, monitoring burden, and pregnancy compatibility. The classic decision points appear in the table below. [1]

Pharmacokinetics & Key Drug Interactions

The way each drug is absorbed, metabolised, and cleared dictates its interactions and its monitoring. Methotrexate is cleared mainly by the kidney, and reduced renal function or interfering drugs convert a tolerable weekly dose into a toxic one: concurrent NSAID use has been associated with reduced methotrexate clearance and toxicity, an effect observed at mean weekly doses of 15 to 20 mg but not with a starting dose of 7.5 mg. In a systematic review of methotrexate cutaneous ulceration, baseline renal dysfunction, concurrent NSAID use and absent folic acid supplementation were the key risk factors for fatal toxicity, and 30 percent of cases followed mistakenly high doses.[13][12]

Azathioprine has no intrinsic activity; it is a pro-drug whose fate depends on the balance between TPMT (inactivating) and xanthine oxidase (inactivating) on one side and HGPRT (activating) on the other. The clinical consequence is that xanthine oxidase inhibition by allopurinol is dangerous: during concurrent therapy the azathioprine dose should be reduced by at least two thirds with close haematological monitoring, because myelosuppression still occurs — in one transplant cohort 46 percent of patients became leucopenic within three months despite dose reduction. Febuxostat, the alternative xanthine oxidase inhibitor, is contraindicated with azathioprine.[15][16]

Ciclosporin and tacrolimus are both narrow-therapeutic-index drugs metabolised by CYP3A4 and substrates of P-glycoprotein. Inhibitors of CYP3A4 (macrolides such as erythromycin and clarithromycin, azole antifungals, diltiazem, verapamil, grapefruit juice, HIV protease inhibitors) raise levels and precipitate nephrotoxicity; inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbitone, St John's wort) lower levels and cause treatment failure. Nephrotoxicity is additive with aminoglycosides, NSAIDs, tenofovir, and iodinated contrast, and statin myopathy and rhabdomyolysis risk rise when ciclosporin is combined with simvastatin or atorvastatin. [1]

Mycophenolate absorption is reduced by antacids, iron, sevelamer, and cholestyramine; tacrolimus and ciclosporin raise mycophenolate levels. Cyclophosphamide is a pro-drug activated by hepatic CYP2C9 and 3A4, so inducers (phenytoin, rifampicin) increase acrolein formation and cystitis risk while inhibitors blunt efficacy. Dapsone levels are raised by cimetidine, probenecid, and trimethoprim, and its oxidative haemolysis is compounded by other oxidants such as primaquine and sulfonamides. [1]

Biologics, by contrast, have few pharmacokinetic interactions because they are proteins degraded to peptides; methotrexate co-therapy actually lowers anti-drug antibody formation against infliximab and adalimumab and is routinely co-prescribed for that reason. The relevant interactions with biologics are pharmacodynamic: live vaccines are contraindicated, and combination of two biologics increases serious infection without improving efficacy.[1]

JAK inhibitors are metabolised hepatically (tofacitinib largely by CYP3A4; baricitinib and upadacitinib partly by CYP2C9) so strong inhibitors (ketoconazole, fluconazole, clarithromycin) raise exposure; strong inducers (rifampicin) reduce it. They raise lipid levels and may potentiate statins and immunosuppressive co-therapy.[7]

Pre-treatment Assessment & Counselling

Before any systemic immunosuppressant is started, every patient undergoes the same baseline assessment, on top of which each drug adds its specific test. Skipping this bundle is the commonest source of preventable harm. [1]

[1]

Screening & Monitoring Investigations

The monitoring schedule is drug-specific, but a few rules are universal: cytotoxic agents need a full blood count, hepatic agents need liver function tests, and renal agents need creatinine and blood pressure. The non-negotiable pre-treatment biomarkers are listed below. [1]

For methotrexate, check FBC and LFTs every one to two weeks for the first month, then every two to three months; serial procollagen-III N-terminal peptide (PIIINP) or transient elastography surveys for hepatic fibrosis, and a chest X-ray plus prompt review of any respiratory symptom screens for pneumonitis.[6] For azathioprine, FBC is weekly for the first four to eight weeks then monthly, with LFTs; a falling mean corpuscular volume or rising mean corpuscular haemoglobin can herald myelosuppression. For ciclosporin, blood pressure and creatinine are checked every two weeks until the dose stabilises then monthly; creatinine must not rise by more than 30 percent from baseline and, if it does, the dose is reduced or the drug stopped.[1] For dapsone, FBC weekly for the first month then monthly, with a methaemoglobin level if cyanosis or dyspnoea appears.[3] For biologics, a TB screen (IGRA plus chest X-ray), HBV, HCV, and HIV are mandatory before the first dose; routine bloods are minimal except for rituximab, which requires immunoglobulin and CD19 monitoring.[9]

Drug Profiles — Definitive Guide

This section is the core of the topic. Each agent is presented with mechanism, indication, dose, monitoring, toxicity, interactions, and pregnancy category. [1]

Corticosteroids

Mechanism. Glucocorticoid-receptor mediated transrepression of NF-kappa-B and AP-1; reduced TNF, IL-1, IL-2, IL-6; lymphocyte apoptosis. Indication. Acute control of pemphigus vulgaris, bullous pemphigoid, severe atopic dermatitis flares, cutaneous lupus, dermatomyositis, and Stevens-Johnson syndrome/toxic epidermal necrolysis (in selected cases).[9]

Dose. Prednisone-equivalent doses of roughly 1 to 1.5 mg/kg/day have been used for pemphigus induction in real-world cohorts, with gradual tapering once disease is controlled. Glucocorticoid therapy should not be stopped completely until adrenal function has recovered, because abrupt cessation risks glucocorticoid-induced adrenal insufficiency. Monitoring. Regular reassessment of the minimum effective dose, with counselling on the features of adrenal insufficiency and of glucocorticoid withdrawal syndrome during the taper.[20][22]

[22]

Methotrexate

Mechanism. Folate analogue inhibiting DHFR and thymidylate synthase; anti-inflammatory at low dose via adenosine. Indication. First-line systemic for plaque psoriasis and psoriatic arthritis; atopic dermatitis; bullous pemphigoid; cutaneous T-cell lymphoma; sarcoidosis.[1][6]

Dose. Methotrexate for psoriasis is dosed once weekly. In randomised trials the start dose ranged from 5 to 25 mg per week — most commonly 7.5 mg or 15 mg — while guidelines recommend 5 to 15 mg per week; a test dose was used in some trials and is recommended by several guidelines, and folic acid supplementation is recommended by most guidelines. Side effects. Hepatotoxicity, myelosuppression and mucositis; methotrexate pneumonitis most often presents with a subacute dry cough and dyspnoea with or without fever, and the drug must be withheld when these symptoms appear.[11][13]

[1]

Azathioprine

Mechanism. Pro-drug to 6-mercaptopurine then 6-thioguanine nucleotides; impairs lymphocyte DNA synthesis. Indication. Atopic dermatitis, pemphigus vulgaris, bullous pemphigoid, chronic actinic dermatitis, cutaneous lupus, pyoderma gangrenosum.[3][9]

Dose. Adjusted to clinical response and the full blood count, guided by pre-treatment thiopurine methyltransferase (TPMT) assessment. Mandatory pre-test. The British Association of Dermatologists guideline recommends pre-treatment measurement of red-blood-cell TPMT activity before azathioprine is started, because low activity predisposes to myelosuppression. Monitoring. Routine safety monitoring of the blood count and liver function is recommended for every patient on azathioprine. Interactions. The single most dangerous interaction in dermatology: allopurinol inhibits xanthine oxidase and shunts 6-MP toward active metabolites — reduce the azathioprine dose by at least two thirds with close haematological monitoring, or avoid the combination; febuxostat is contraindicated with azathioprine.[14][15][16]

Ciclosporin

Mechanism. Calcineurin inhibitor; binds cyclophilin; blocks NFAT and IL-2 transcription. Indication. Rapid control of severe, flaring psoriasis or atopic dermatitis; pyoderma gangrenosum; as a short bridge to a steroid-sparing agent.[1]

Dose. 2.5 to 5 mg/kg/day orally: a starting dose of 5 mg/kg produces PASI 75 in 50 to 97 percent of patients, lower doses of 2.5 mg/kg in 28 to 85 percent, and remission is maintained at doses of at least 3 mg/kg/day. Monitoring. Serum creatinine must be monitored throughout — more than 50 percent of patients may show a creatinine rise over 30 percent of baseline if treatment is prolonged for 2 years — and cumulative treatment duration is preferably limited to 2 years or less. Side effects. Nephrotoxicity and hypertension are the dominant toxicities and susceptibility varies between individuals, so careful monitoring is required; single or intermittent short courses are safer than continuous treatment, and ciclosporin is ideally suited to crisis intervention.[18][17]

Mycophenolate mofetil

Mechanism. Hydrolysed to mycophenolic acid; inhibits IMPDH and de-novo purine synthesis in lymphocytes. Indication. Pemphigus vulgaris, bullous pemphigoid, cutaneous lupus, pyoderma gangrenosum.[9]

Dose. 2 g/day was the comparator dose in the PEMPHIX pemphigus trial, and 2000 mg daily was the median dose in a pyoderma gangrenosum case series in which more than 80 percent of patients achieved healing or adequate disease control. Monitoring. Myelosuppression and gastrointestinal upset were the most common adverse effects in that series (each 18 percent), so the full blood count is monitored during therapy. Evidence. Rituximab was superior to mycophenolate mofetil 2 g/day for sustained complete remission of pemphigus vulgaris at week 52.[19][30]

Cyclophosphamide

Mechanism. Alkylating agent; hepatic activation to phosphoramide mustard (DNA cross-links) and acrolein (bladder toxin). Indication. Severe vasculitis (ANCA-associated, cryoglobulinaemic, polyarteritis nodosa), refractory pemphigus.[4]

Dose. Dose and schedule are protocolised by indication (oral daily dosing or intermittent intravenous pulses), with adequate hydration as the baseline preventive measure against bladder toxicity. Side effects. Haemorrhagic cystitis — the caustic metabolite acrolein damages the bladder urothelium; MESNA, the most widely used uroprotective agent, neutralises acrolein, and prophylaxis combines mesna with a high urine flow.[24][25]

[1]

Dapsone

Mechanism. Inhibits myeloperoxidase and neutrophil integrin function; suppresses neutrophil-mediated cytotoxicity. Indication. Dermatitis herpetiformis (pathognomonic response), linear IgA bullous dermatosis, leprosy (antibacterial at full dose), neutrophilic dermatoses (Sweet syndrome, pyoderma gangrenosum), Behcet disease, and IgA pemphigus.[3]

Mandatory pre-test. Systemic dapsone requires screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency before the first dose and routine monitoring of blood counts; its adverse effects include neuropathy, blood dyscrasia and hypersensitivity syndrome. Haemolysis and methaemoglobinaemia are the classic toxicities — they are more likely in G6PD deficiency but can occur even with normal G6PD levels, so haemoglobin, reticulocytes and oxygen saturation should be checked regularly during therapy.[27][29][28]

Thalidomide

Mechanism. Reduces tumour necrosis factor-alpha and has immunomodulatory and anti-angiogenic properties. Use. Effective in severe dermatological conditions with an inflammatory or autoimmune basis. Pregnancy prevention. Use is strictly monitored and precautions are taken to ensure safe and correct use by both prescriber and patient because of teratogenicity, and the other dose-limiting toxicity is peripheral neuropathy.[26][31]

Biologics

The biologics are monoclonal antibodies (or receptor-Fc fusions) directed against specific cytokines. They are grouped by target. Before any biologic, screen for latent tuberculosis (IGRA plus chest X-ray), hepatitis B and C, and HIV, because reactivation is the class's headline infectious risk.[1][9]

TNF-alpha inhibitors. Etanercept, adalimumab, certolizumab pegol and infliximab are TNF-alpha inhibitors approved for plaque psoriasis and psoriatic arthritis.[1]

IL-17 inhibitors. Secukinumab, ixekizumab, brodalumab and bimekizumab are interleukin-17 pathway inhibitors used for plaque psoriasis and psoriatic arthritis.[1]

IL-23 and IL-12/23 inhibitors. Ustekinumab (anti-IL-12/23 p40, weight-based subcutaneously at weeks 0 and 4 then every 12 weeks), guselkumab (anti-IL-23 p19, at weeks 0, 4 then every 8 weeks), risankizumab (anti-IL-23 p19, at weeks 0, 4 then every 12 weeks), and tildrakizumab (anti-IL-23 p19). These are among the best-tolerated biologics, with upper-respiratory infection and candidiasis the main toxicities and low TB-reactivation risk.[1]

Type 2 cytokine blockers (atopic dermatitis). Dupilumab 600 mg subcutaneously then 300 mg every 2 weeks is an established systemic option for moderate-to-severe atopic dermatitis, and in a phase 3 trial in children aged 6 months to under 6 years weight-based dupilumab (200 mg for bodyweight 5 to under 15 kg, 300 mg for 15 to under 30 kg, every 4 weeks) significantly improved disease severity versus placebo, with conjunctivitis more frequent with dupilumab than placebo.[8][21]

B-cell depletion. Rituximab (anti-CD20) depletes B lymphocytes. In the PEMPHIX trial, rituximab 1000 mg intravenously on days 1, 15, 168 and 182 produced sustained complete remission at week 52 in 40 percent of patients with moderate-to-severe pemphigus vulgaris versus 10 percent with mycophenolate mofetil 2 g/day, with fewer disease flares and a lower cumulative glucocorticoid dose, though serious adverse events were more frequent with rituximab. Regimens of 1000 mg on days 0 and 15 or 375 mg/m2 weekly for 4 weeks are both used in practice.[19][20]

Other biologics. Omalizumab (anti-IgE) for chronic spontaneous urticaria. Canakinumab (anti-IL-1 beta) for cryopyrin-associated periodic syndromes, Schnitzler syndrome, and severe neutrophilic dermatoses. Eculizumab (anti-C5) for paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome (neisseria vaccination mandatory). [1]

JAK inhibitors (small molecules)

The oral Janus kinase inhibitors block intracellular phosphorylation downstream of type I and type II cytokine receptors. Tofacitinib (JAK1/3), baricitinib (JAK1/2), upadacitinib (JAK1-selective), abrocitinib (JAK1, for atopic dermatitis), and ruxolitinib (topical, JAK1/2 for atopic dermatitis and vitiligo). They are used for atopic dermatitis (upadacitinib, abrocitinib, baricitinib), alopecia areata (baricitinib, ruxolitinib), vitiligo (ruxolitinib topical, upadacitinib), and psoriatic arthritis (tofacitinib).[7][10]

Monitoring. FBC, lipids, and LFTs at baseline and serially; screen for TB, HBV, HCV before start. Toxicities. Herpes zoster (higher than with biologics, particularly in Asian populations — consider shingles vaccination), nasopharyngitis and acne, cytopenias, lipid elevation, and the class boxed warnings drawn from the ORAL Surveillance trial of tofacitinib in rheumatoid arthritis: increased major adverse cardiovascular events, malignancy, thrombosis (venous and arterial), and mortality in older, at-risk patients. These warnings now extend across the class and prompt caution in patients over 50 with cardiovascular or malignancy risk factors.[7]

Acute Toxicities & Resuscitation

A handful of acute presentations on immunosuppression are time-critical and must be managed on a protocol. These are the emergencies the examiner uses to test whether the candidate understands the drugs, not just the diseases. [1]

[1]

For methotrexate pneumonitis (subacute dry cough and dyspnoea with or without fever), the drug must be withheld while infection is excluded, with corticosteroids and supportive care to follow. For dapsone methaemoglobinaemia, methylene blue 1 to 2 mg/kg intravenously is the standard antidote, but patients with G6PD deficiency — and dapsone-exposed patients generally — carry special risks and need specialist toxicology input. For cyclophosphamide-induced haemorrhagic cystitis, prevention rests on aggressive hydration and MESNA, which neutralises acrolein. For glucocorticoid-induced adrenal insufficiency, steroids must be tapered rather than stopped, and therapy should not be discontinued until adrenal function has recovered.[13][23][24][22]

Special Populations

Pregnancy and lactation

Drug choice in a pregnant or breast-feeding patient with severe skin disease is constrained by teratogenicity and by drug transfer into milk. The safest systemic agents are prednisolone (placenta-inactivated), ciclosporin, tacrolimus, intravenous immunoglobulin, and increasingly dupilumab (large molecule, minimal placental transfer, reassuring registry data).[3]

Children

Weight-based dosing applies throughout. In a phase 3 trial, dupilumab 200 mg (bodyweight 5 to under 15 kg) or 300 mg (15 to under 30 kg) every 4 weeks significantly improved moderate-to-severe atopic dermatitis in children aged 6 months to under 6 years, with a safety profile similar to placebo apart from more frequent conjunctivitis.[21]

Elderly and the comorbid

Reduce doses for renal function (methotrexate, ciclosporin, dapsone), anticipate drug interactions from polypharmacy, provide bone protection (calcium, vitamin D, a bisphosphonate) with long-term steroids, and screen cardiovascular and malignancy risk before biologics and JAK inhibitors. [1]

Complications & Pitfalls

The complications map to mechanism. Cytotoxic drugs cause cytopenia and teratogenicity; renal-acting drugs cause hypertension and nephrotoxicity; biologics reactivate infection; JAK inhibitors raise cardiovascular and thrombotic risk. The pitfalls that examiners reward awareness of are the preventable ones. [1]

[1]

Prognosis & Disposition

Most inflammatory and bullous dermatoses are controlled, not cured, by systemic immunosuppression. Ciclosporin is a short bridge (1 to 2 years) to a steroid-sparing or biologic agent because cumulative nephrotoxicity is inexorable. Methotrexate, azathioprine, and mycophenolate are maintained long-term with monitoring; biologics sustain disease control for years, though immunogenicity (anti-drug antibodies to infliximab and adalimumab) can erode efficacy and force switching. Rituximab gives long pemphigus remission but B-cell depletion lasts 6 to 12 months and re-treatment is usual. The disposition question — when to refer, when to admit, when to switch — hinges on disease severity, response, and toxicity; a patient failing first conventional therapy should be referred to a specialist unit for a biologic or small-molecule assessment.[1][8]

Evidence, Guidelines & Regional Differences

The evidence base is mature for psoriasis and atopic dermatitis and evolving rapidly for biologics and JAK inhibitors. The landmark trials and guidelines a fellowship candidate should know include the following. [1]

[19]

The AAD-NPF psoriasis guidelines (Menter et al.) list methotrexate, ciclosporin, and acitretin as the first-line conventional agents and place TNF, IL-17, and IL-23 inhibitors for moderate-to-severe disease.[6] The 2023 AAAAI/ACAAI atopic dermatitis guidelines describe dupilumab as first-line systemic and the JAK inhibitors as second-line for moderate-to-severe disease.[3] The EULAR recommendations cover connective-tissue disease systemic therapy.[4]

[1] [1]

Exam Pearls

Self-test: a patient on azathioprine is started on allopurinol for gout — what happens and why?

Allopurinol inhibits xanthine oxidase, the enzyme that detoxifies the azathioprine metabolite 6-mercaptopurine to thiouric acid. 6-mercaptopurine is therefore shunted toward 6-thioguanine nucleotides, which accumulate and cause severe, potentially fatal myelosuppression. The combination must be avoided, or the azathioprine dose reduced by about 70 percent with intense blood-count monitoring. This is the single most dangerous drug interaction in dermatologic immunosuppression.

[1]

Exam application bank (NEET-PG / INICET)

One-line answer

Systemic immunosuppressants in dermatology: corticosteroids (prednisolone 0.5-1 mg/kg/day taper; methylprednisolone 0.5-1 g IV pulses; diabetes, osteoporosis, HTN, cataracts, adrenal suppression), methotrexate (7.5-25 mg WEEKLY + folic acid; LFT/FBC; hepatotoxicity, pneumonitis; folinic acid rescue), azathioprine (1-3 mg/kg/day; check TPMT first; FATAL allopurinol interaction), ciclosporin (2.5-5 mg/kg/day; creatinine +30% = stop; max 2 years), mycophenolate mofetil (1-2 g/day; teratogenic), cyclophosphamide (MESNA for haemorrhagic cystitis), tacrolimus, dapsone (check G6PD; haemolysis, methaemoglobinaemia), hydroxycarbamide, thalidomide (pregnancy prevention), biologics (TNF, IL-17, IL-23, IL-4Ra, IL-13, CD20; TB screening), and JAK inhibitors (tofacitinib, baricitinib, upadacitinib; VTE/MACE warnings). [1]

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Systemic immunosuppressants.

[1] [1]

References

1. [1]Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review JAMA, 2020.PMID 32427307
2. [2]Butler DC, Berger T, Elmariah S, et al. Chronic Pruritus: A Review JAMA, 2024.PMID 38809527
3. [3]Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations Ann Allergy Asthma Immunol, 2024.PMID 38108679
4. [4]Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies Ann Rheum Dis, 2020.PMID 31672775
5. [5]Clanner-Engelshofen BM, Bernhard D, Dargatz S, et al. S2k guideline: Rosacea J Dtsch Dermatol Ges, 2022.PMID 35929658
6. [6]Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies J Am Acad Dermatol, 2020.PMID 32119894
7. [7]King BA, Craiglow BG. Janus kinase inhibitors for alopecia areata J Am Acad Dermatol, 2023.PMID 37591562
8. [8]Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis JAMA Dermatol, 2022.PMID 35293977
9. [9]Schmidt E, Kasperkiewicz M, Joly P. Pemphigus Lancet, 2019.PMID 31498102
10. [10]Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review Front Immunol, 2021.PMID 34868078
11. [11]Menting SP, Dekker PM, Limpens J, et al. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. Acta Derm Venereol, 2016.PMID 25721372
12. [12]Berna R, Rosenbach M, Margolis DJ, et al. Methotrexate Cutaneous Ulceration: A Systematic Review of Cases. Am J Clin Dermatol, 2022.PMID 35486323
13. [13]Kremer JM. Methotrexate update. Scand J Rheumatol, 1996.PMID 8996467
14. [14]Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol, 2004.PMID 15606506
15. [15]Cummins D, Sekar M, Halil O, et al. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation, 1996.PMID 8669118
16. [16]Logan JK, Wickramaratne Senarath Yapa S, Muñoz M, et al. Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature. Pharmacotherapy, 2020.PMID 31885095
17. [17]Berth-Jones J. The use of ciclosporin in psoriasis. J Dermatolog Treat, 2005.PMID 16428145
18. [18]Maza A, Montaudié H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol, 2011.PMID 21388455
19. [19]Werth VP, Joly P, Mimouni D, et al. Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. N Engl J Med, 2021.PMID 34097368
20. [20]Snast I, Spitzer L, Hodak E, et al. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience. Dermatology, 2021.PMID 32756069
21. [21]Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2022.PMID 36116481
22. [22]Prete A, Bancos I, et al. Glucocorticoid induced adrenal insufficiency. BMJ, 2021.PMID 34253540
23. [23]Clifton J 2nd, Leikin JB. Methylene blue. Am J Ther, 2003.PMID 12845393
24. [24]Matz EL, Hsieh MH. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. Urology, 2017.PMID 27566144
25. [25]deVries CR, Freiha FS. Hemorrhagic cystitis: a review. J Urol, 1990.PMID 2403595
26. [26]Hussain K, Patel P, Roberts N. The role of thalidomide in dermatology. Clin Exp Dermatol, 2022.PMID 34779533
27. [27]Pate DA, Johnson LS, Tarbox MB. Leukocytoclastic vasculitis resolution with topical dapsone. Cutis, 2017.PMID 28686752
28. [28]Pradhan S, Dash G. Dapsone induced hemolysis and drop in saturation in normal glucose-6-phosphate dehydrogenase level patients - alarming presentation of poor man's drug: A series of 12 cases and review of literature. Indian J Pharmacol, 2026.PMID 42583982
29. [29]Hu Y, Geere M, Awan M, et al. Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria. Hematology, 2022.PMID 36444994
30. [30]Hrin ML, Bashyam AM, Huang WW, et al. Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review. Int J Dermatol, 2021.PMID 33739458
31. [31]Wines NY, Cooper AJ, Wines MP. Thalidomide in dermatology. Australas J Dermatol, 2002.PMID 12423428